Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience

Parikh, 2013, Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease, Inflamm Bowel Dis, 19, 1691, 10.1097/MIB.0b013e318281f538 Lam, 2014, Vedolizumab for ulcerative colitis and Crohn’s disease: results and implications of GEMINI studies, Immunotherapy, 6, 963, 10.2217/imt.14.66 Sandborn, 2013, Vedolizumab as induction and maintenance therapy for Crohn’s disease, N Eng J Med, 369, 711, 10.1056/NEJMoa1215739 Sands, 2014, Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed, Gastroenterology, 147, 618, 10.1053/j.gastro.2014.05.008 Shelton, 2015, Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort, Inflamm Bowel Dis, 21, 2879, 10.1097/MIB.0000000000000561 Baumgart, 2016, Vedolizumab induction therapy for inflammatory bowel disease in clinical practice—a nationwide consecutive German cohort study, Aliment Pharmacol Ther, 43, 1090, 10.1111/apt.13594 Dulai, 2016, The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium, Am J Gastroenterol, 111, 1147, 10.1038/ajg.2016.236 Stallmach, 2016, Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease—a prospective multicenter observational study, Aliment Pharmacol Ther, 44, 1199, 10.1111/apt.13813 Vivio, 2016, Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice, J Crohns Colitis, 10, 402, 10.1093/ecco-jcc/jjv226 Allegretti, 2017, Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab, Dig Dis Sci, 62, 1590, 10.1007/s10620-017-4549-3 Eriksson, 2017, Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish national quality registry for inflammatory bowel disease (SWIBREG), Scand J Gastroenterol, 52, 722, 10.1080/00365521.2017.1304987 Kopylov, 2017, Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease-the Israeli real-world experience, Inflamm Bowel Dis, 23, 404, 10.1097/MIB.0000000000001039 Stevens, 2017, Vedolizumab therapy is associated with an improvement in sleep quality and mood in inflammatory bowel diseases, Dig Dis Sci, 62, 197, 10.1007/s10620-016-4356-2 Engel, 2018, Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis, J Crohns Colitis, 12, 245, 10.1093/ecco-jcc/jjx143 Feagan, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 369, 699, 10.1056/NEJMoa1215734 Lewis, 2008, Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis, Inflamm Bowel Dis, 14, 1660, 10.1002/ibd.20520 Narula, 2018, Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium, Am J Gastroenterol, 10.1038/s41395-018-0162-0 Peyrin-Biroulet, 2018, Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn’s disease or ulcerative colitis: a systematic review and meta-analysis. Clinical gastroenterology and hepatology: the official clinical practice, J Am Gastroenterol Assoc Ben-Horin, 2014, Tailoring anti-TNF therapy in IBD: drug levels and disease activity, Nat Rev Gastroenterol Hepatol, 11, 243, 10.1038/nrgastro.2013.253 Ungar, 2016, Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clinical gastroenterology and hepatology: the official clinical practice, J Am Gastroenterol Assoc, 14, 550 Ungar, 2017, Association of vedolizumab level, anti-drug antibodies, and alpha4beta7 occupancy with response in patients with inflammatory bowel diseases. Clinical gastroenterology and hepatology: the official clinical practice, J Am Gastroenterol Assoc, 16, 697 Ungar, 2017, Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab, Aliment Pharmacol Ther, 45, 276, 10.1111/apt.13862 Williet, 2017, Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. Clinical gastroenterology and hepatology: the official clinical practice, J Am Gastroenterol Assoc, 15, 1750 Rosario, 2016, Vedolizumab pharmacokinetics, pharmacodynamics, safety, and tolerability following administration of a single, ascending, intravenous dose to healthy volunteers, Clin Drug Investig, 36, 913, 10.1007/s40261-016-0437-4